User profiles for Bernard H.E. Jansen
 | Bernard Henk-Erik JansenAmsterdam University Medical Centers, VU University Verified email at vumc.nl Cited by 631 |
[HTML][HTML] Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis
RW Jansen, P van Amstel, RM Martens, IE Kooi… - Oncotarget, 2018 - ncbi.nlm.nih.gov
With targeted treatments playing an increasing role in oncology, the need arises for fast non-invasive
genotyping in clinical practice. Radiogenomics is a rapidly evolving field of …
genotyping in clinical practice. Radiogenomics is a rapidly evolving field of …
[HTML][HTML] Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
MCF Cysouw, BHE Jansen, T van de Brug… - European journal of …, 2021 - Springer
Purpose Quantitative prostate-specific membrane antigen (PSMA) PET analysis may provide
for non-invasive and objective risk stratification of primary prostate cancer (PCa) patients. …
for non-invasive and objective risk stratification of primary prostate cancer (PCa) patients. …
Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix criteria for …
BHE Jansen, PJ van Leeuwen, M Wondergem… - European urology …, 2021 - Elsevier
… Author contributions: Bernard HE Jansen had full access to all the data in the study and
takes responsibility for the integrity of the data and the accuracy of the data analysis. …
takes responsibility for the integrity of the data and the accuracy of the data analysis. …
Simplified methods for quantification of 18F-DCFPyL uptake in patients with prostate cancer
BHE Jansen, M Yaqub, J Voortman… - Journal of nuclear …, 2019 - Soc Nuclear Med
Radiolabeled prostate-specific membrane antigen (PSMA) PET has demonstrated promising
results for prostate cancer (PCa) imaging. Quantification of PSMA radiotracer uptake is …
results for prostate cancer (PCa) imaging. Quantification of PSMA radiotracer uptake is …
[HTML][HTML] Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the …
…, PJ van der Voorn, BHE Jansen… - European journal of …, 2022 - Springer
Purpose Multiparametric magnetic resonance imaging (mpMRI) is a well-established imaging
method for localizing primary prostate cancer (PCa) and for guiding targeted prostate …
method for localizing primary prostate cancer (PCa) and for guiding targeted prostate …
Healthy tissue uptake of 68Ga-prostate-specific membrane antigen, 18F-DCFPyL, 18F-fluoromethylcholine, and 18F-dihydrotestosterone
BHE Jansen, GM Kramer, MCF Cysouw… - Journal of Nuclear …, 2019 - Soc Nuclear Med
PET is increasingly used for prostate cancer (PCa) diagnostics. Important PCa radiotracers
include 68 Ga-prostate-specific membrane antigen HBED-CC ( 68 Ga-PSMA), 18 F-DCFPyL, …
include 68 Ga-prostate-specific membrane antigen HBED-CC ( 68 Ga-PSMA), 18 F-DCFPyL, …
Repeatability of quantitative 18F-DCFPyL PET/CT measurements in metastatic prostate cancer
Quantitative evaluation of radiolabeled prostate-specific membrane antigen (PSMA) PET
scans may be used to monitor treatment response in patients with prostate cancer (PCa). To …
scans may be used to monitor treatment response in patients with prostate cancer (PCa). To …
Adding multiparametric MRI to the MSKCC and Partin nomograms for primary prostate cancer: Improving local tumor staging?
BHE Jansen, JA Nieuwenhuijzen… - … Oncology: Seminars and …, 2019 - Elsevier
Introduction and objectives As a single diagnostic modality, multiparametric MRI (mpMRI) has
imperfect accuracy to detect locally advanced prostate cancer (T-stages 3-4). In this study …
imperfect accuracy to detect locally advanced prostate cancer (T-stages 3-4). In this study …
Lesion detection and interobserver agreement with advanced image reconstruction for 18F-DCFPyL PET/CT in patients with biochemically recurrent prostate cancer
BHE Jansen, RW Jansen, M Wondergem… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Biochemically recurrent prostate cancer (BCR) is the main indication to perform prostate-specific
membrane antigen PET/CT. However, localizing BCR with prostate-specific membrane …
membrane antigen PET/CT. However, localizing BCR with prostate-specific membrane …
[HTML][HTML] Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
D Meijer, BHE Jansen, M Wondergem, YJL Bodar… - Plos one, 2020 - journals.plos.org
Purpose Radiolabeled Prostate-Specific Membrane Antigen (PSMA) PET/CT is the current
standard-of-care for lesion detection in patients with biochemically recurrent (BCR) prostate …
standard-of-care for lesion detection in patients with biochemically recurrent (BCR) prostate …